| 依达拉奉联合奥扎格雷钠治疗进展性脑梗死的近期疗效观察 |
| 投稿时间：2010-01-28 修订日期：2010-05-11 点此下载全文 |
| 引用本文：窦汝香,李卓星,林凯思.依达拉奉联合奥扎格雷钠治疗进展性脑梗死的近期疗效观察[J].医学研究杂志,2010,39(7):80-82 |
| DOI：
|
| 摘要点击次数: 1208 |
| 全文下载次数: 1064 |
|
| 基金项目:深圳市龙岗区科技计划资助项目(深龙科［2008］24-26);深圳市科技计划非资助项目（卫生医疗类）(200903224) |
|
| 中文摘要:目的检测依达拉奉联合奥扎格雷钠治疗进展性脑梗死的疗效，探讨其治疗机制。方法选择急性进展性脑梗死患者85例，随机分为依达拉奉与奥扎格雷钠联合治疗组（n=43）和奥扎格雷钠单药对照组（n=42），治疗疗程共14天。在治疗前、后进行神经功能缺损程度（the nantional institute of health stroke scale，NIHSS）、日常生活活动能力（activities of daily living，ADL）和临床疗效的评定。结果治疗组患者的NIHSS、ADL评分均有明显改善，显著高于对照组（P<0.01）；临床有效率达9048%，显著高于对照组（P<0.05），两组均未见明显的用药不良反应。结论依达拉奉联合奥扎格雷钠治疗进展性脑梗死疗效较好，安全性好，值得进一步观察及探讨。 |
| 中文关键词:脑梗死 依达拉奉 奥扎格雷 治疗结果 |
| |
| The Effect of Edaravone Combined Ozagrel Sodium in Treating Progressive Cerebral Infarction |
|
|
| Abstract:ObjectiveTo investigate the effect of Edaravone combined Ozagrel sodium in treating progressive cerebral infarction. Methods85 patients with acute progressive cerebral infarction were randomly divided into two groups: treatment group with Edaravone combined Ozagrel sodium(n=43) and control group (n=42). Control group was only allocated Ozagrel sodium treating for 14 days. The primary efficacy was evaluated by NIHSS(the National Institutes of Health stroke scale，NIHSS), ADL(Activities of daily living，ADL) and clinical deeective.ResultsOur study showed that the score in ADL and NIHSS in treatment group was higher than that of control group.Edaravone combined Ozagrel sodium could significantly reduce neurological deficits and the effective rate was up to 90.48%,as compared with control group.ConclusionEdaravone combined Ozagrel sodium are remarkable effective on PCI and have no obvious advers reation. |
| keywords:Cerebral infarction Edaravone Ozagrel sodium Treatment outcome |
| 查看全文 查看/发表评论 下载PDF阅读器 |
